What is ATAI Life Sciences NV Financial Strength?
ATAI Life Sciences NV has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
ATAI Life Sciences NV did not have earnings to cover the interest expense.
ATAI Life Sciences NV's debt to revenue ratio for the quarter that ended in Dec. 2023 was 265.86.
As of today, ATAI Life Sciences NV's Altman Z-Score is 1.83.
Competitive Comparison of ATAI Life Sciences NV's Financial Strength
For the Biotechnology subindustry, ATAI Life Sciences NV's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ATAI Life Sciences NV's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Financial Strength distribution charts can be found below:
* The bar in red indicates where ATAI Life Sciences NV's Financial Strength falls into.
ATAI Life Sciences NV Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
ATAI Life Sciences NV's Interest Expense for the
months ended in Dec. 2023 was $-0.69 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-31.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.87 Mil.
ATAI Life Sciences NV's Interest Coverage for the quarter that ended in Dec. 2023 is
| ATAI Life Sciences NV did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
ATAI Life Sciences NV's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
ATAI Life Sciences NV has a Z-score of 1.83, indicating it is in Grey Zones. This implies that ATAI Life Sciences NV is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 1.83 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description
Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
| Florian Brand |
officer: See Remarks |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Anne Nagengast Johnson |
officer: Chief Accounting Officer |
C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
| Apeiron Investment Group Ltd. |
10 percent owner |
BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
| Sahil Kirpekar |
officer: Chief Business Officer |
C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179 |
| Stephen Bardin |
officer: Chief Financial Officer |
C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117 |
| Gregory L Weaver |
officer: Chief Financial Officer |
185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107 |
| Andrea Heslin Smiley |
director |
600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
| Michael Auerbach |
director |
158 HESTER STREET, APT 7F, NEW YORK NY 10013 |
| Amir H Kalali |
director |
4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121 |
| Christian Angermayer |
director, 10 percent owner |
BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605 |
| Rosnay Alexis De |
director |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Srinivas Rao |
officer: See Remarks |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Sabrina Martucci Johnson |
director |
11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
| Jason Camm |
director |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
| Presight Ii, Lp |
10 percent owner |
C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATAI has been successfully added to your